Literature DB >> 33343033

A Multi-Mode System for Myocardial Functional and Physiological Assessment during Ex Situ Heart Perfusion.

Thomas Duignan1, Alvise Guariento1, Ilias P Doulamis1, Takashi Kido1, William L Regan1, Mossab Saeed1, David M Hoganson1, Sitaram M Emani1, Pedro J Del Nido1, James D McCully1, Gregory S Matte1.   

Abstract

Ex situ heart perfusion (ESHP) has proven to be an important and valuable step toward better preservation of donor hearts for heart transplantation. Currently, few ESHP systems allow for a convenient functional and physiological evaluation of the heart. We sought to establish a simple system that provides functional and physiological assessment of the heart during ESHP. The ESHP circuit consists of an oxygenator, a heart-lung machine, a heater-cooler unit, an anesthesia gas blender, and a collection funnel. Female Yorkshire pig hearts (n = 10) had del Nido cardioplegia (4°C) administered, excised, and attached to the perfusion system. Hearts were perfused retrogradely into the aortic root for 2 hours before converting the system to an isovolumic mode or a working mode for further 2 hours. Blood samples were analyzed to measure metabolic parameters. During the isovolumic mode (n = 5), a balloon inserted in the left ventricular (LV) cavity was inflated so that an end-diastolic pressure of 6-8 mmHg was reached. During the working mode (n = 5), perfusion in the aortic root was redirected into left atrium (LA) using a compliance chamber which maintained an LA pressure of 6-8 mmHg. Another compliance chamber was used to provide an afterload of 40-50 mmHg. Hemodynamic and metabolic conditions remained stable and consistent for a period of 4 hours of ESHP in both isovolumic mode (LV developed pressure: 101.0 ± 3.5 vs. 99.7 ± 6.8 mmHg, p = .979, at 2 and 4 hours, respectively) and working mode (LV developed pressure: 91.0 ± 2.6 vs. 90.7 ± 2.5 mmHg, p = .942, at 2 and 4 hours, respectively). The present study proposed a novel ESHP system that enables comprehensive functional and metabolic assessment of large mammalian hearts. This system allowed for stable myocardial function for up to 4 hours of perfusion, which would offer great potential for the development of translational therapeutic protocols to improve dysfunctional donated hearts. © Copyright 2020 AMSECT.

Entities:  

Keywords:  cardioplegia; ex situ heart perfusion; heart transplant; myocardial function

Mesh:

Year:  2020        PMID: 33343033      PMCID: PMC7728502          DOI: 10.1182/ject-2000034

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  24 in total

1.  Posttransplant function of a nonbeating heart is predictable by an ex vivo perfusion method.

Authors:  K Suehiro; M Mohri; H Yamaguchi; M Takagaki; K Hisamochi; T Morimoto; S Sano
Journal:  Ann Thorac Surg       Date:  2001-01       Impact factor: 4.330

2.  Achieving 12 Hour Normothermic Ex Situ Heart Perfusion: An Experience of 40 Porcine Hearts.

Authors:  John M Trahanas; Lucas J Witer; Fares Alghanem; Benjamin S Bryner; Amit Iyengar; Jacob R Hirschl; Mark J Hoenerhoff; Joseph A Potkay; Robert H Bartlett; Alvaro Rojas-Pena; Gabe E Owens; Martin L Bocks
Journal:  ASAIO J       Date:  2016 Jul-Aug       Impact factor: 2.872

3.  Outcome after heart transplantation from donation after circulatory-determined death donors.

Authors:  Simon Messer; Aravinda Page; Richard Axell; Marius Berman; Jules Hernández-Sánchez; Simon Colah; Barbora Parizkova; Kamen Valchanov; John Dunning; Evgeny Pavlushkov; Sendhil K Balasubramanian; Jayan Parameshwar; Yasir Abu Omar; Martin Goddard; Stephen Pettit; Clive Lewis; Anna Kydd; David Jenkins; Christopher J Watson; Catherine Sudarshan; Pedro Catarino; Marie Findlay; Ayyaz Ali; Steven Tsui; Stephen R Large
Journal:  J Heart Lung Transplant       Date:  2017-10-24       Impact factor: 10.247

Review 4.  Normothermic donor heart perfusion: current clinical experience and the future.

Authors:  Simon Messer; Abbas Ardehali; Steven Tsui
Journal:  Transpl Int       Date:  2014-07-07       Impact factor: 3.782

Review 5.  Extracorporeal heart perfusion before heart transplantation: the heart in a box.

Authors:  Peter S Macdonald; Hong C Chew; Mark Connellan; Kumud Dhital
Journal:  Curr Opin Organ Transplant       Date:  2016-06       Impact factor: 2.640

6.  Myocardial Functional Decline During Prolonged Ex Situ Heart Perfusion.

Authors:  Sanaz Hatami; Christopher W White; Shubham Shan; Alois Haromy; Xiao Qi; Martin Ondrus; Alexandra Kinnear; Sayed Himmat; Evangelos Michelakis; Jayan Nagendran; Darren H Freed
Journal:  Ann Thorac Surg       Date:  2019-03-12       Impact factor: 4.330

7.  Normothermic Ex Vivo Heart Perfusion: Effects of Live Animal Blood and Plasma Cross Circulation.

Authors:  Joseph T Church; Fares Alghanem; Kristopher B Deatrick; John M Trahanas; Joseph P Phillips; Min Hee Song; Elena M Perkins; Robert H Bartlett; Alvaro Rojas-Pena; Martin L Bocks; Gabe E Owens
Journal:  ASAIO J       Date:  2017 Nov/Dec       Impact factor: 2.872

8.  A whole blood-based perfusate provides superior preservation of myocardial function during ex vivo heart perfusion.

Authors:  Christopher W White; Devin Hasanally; Paul Mundt; Yun Li; Bo Xiang; Julianne Klein; Alison Müller; Emma Ambrose; Amir Ravandi; Rakesh C Arora; Trevor W Lee; Larry V Hryshko; Stephen Large; Ganghong Tian; Darren H Freed
Journal:  J Heart Lung Transplant       Date:  2014-09-28       Impact factor: 10.247

9.  Sixteen-Hour Ex Vivo Donor Heart Perfusion During Long-Distance Transportation for Heart Transplantation.

Authors:  Rymbay Kaliyev; Serik Bekbossynov; Zhuldyz Nurmykhametova
Journal:  Artif Organs       Date:  2018-12-25       Impact factor: 3.094

10.  Impact of Reperfusion Calcium and pH on the Resuscitation of Hearts Donated After Circulatory Death.

Authors:  Christopher White; Emma Avery; Alison Müller; Sanaz Hatami; Yun Li; Hoa Le; James Thliveris; Rakesh Arora; Trevor Lee; Ian Dixon; Ganghong Tian; Jayan Nagendran; Larry Hryshko; Darren Freed
Journal:  Ann Thorac Surg       Date:  2016-08-12       Impact factor: 5.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.